Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of mitapivat (AG-348) in adults with pyruvate kinase deficiency
jRCT2031210513Completed
- Sponsor
- Agios Pharmaceuticals
- Start
- Oct 2019
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of mitapivat in pyruvate kinase deficiency (PKD), sponsored by Agios Pharmaceuticals. Primary endpoints: Treatment-emergent adverse events, Serious adverse events and 6 more. Started Oct 2019; status: completed.
02
Drugs
mitapivat
03
Conditions
pyruvate kinase deficiency (PKD)
Beyond the preview
Go deeper on jRCT2031210513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210513.